About Ursapharm India Private Limited
Data last updated:
Ursapharm India Private Limited is a foreign private limited company based in New Delhi, Delhi, India, a subsidiary of Ursapharm Arzneimittel Gmbh. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 27 September 2006 and has been in existence for over 20 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24232DL2006FTC154392. Its GSTIN is 07AAACU8541M1ZX (Delhi). The company holds 5 GST registrations, of which 4 are active.
The company has an authorised share capital of ₹1.25 Cr and a paid-up capital of ₹1.2 Cr. It is led by directors including Rohit Jain (Managing Director) and Uwe Hurth.
Its last annual general meeting (AGM) was held on 28 November 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Plot No. : A – 1 Ground Floor Fiee Complex Okhla Industrial Area Phas, E – II, New Delhi, Delhi, India – 110020.
As per the financials filed for FY 2024, the company reported a revenue of ₹6.22 Cr, a decline of 23% compared to the previous year. For the same year it recorded a net profit of ₹58.3 Lakh (net margin 9.4%) and EBITDA of ₹69 Lakh (EBITDA margin 11.1%). Revenue has declined at a compounded annual rate (CAGR) of 7% over three years and 8% over five years.
Court records list 5 cases involving the company, including 4 filed by the company and 1 filed against it; 2 cases are pending. The company has 2 deals on record (2 funding rounds), with disclosed funding of ₹1.19 Cr; the latest was in May 2009. Its 5 peer companies in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading) are compared by revenue, 4 larger and 1 smaller; the largest is Sach Pharmatech Private Limited with revenue of ₹6.24 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website ursapharm.in.
Company details
Contact details
Ursapharm India Private Limited's registered office is in New Delhi, Delhi. Its website is ursapharm.in. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressPlot No. : A – 1 Ground Floor Fiee Complex Okhla Industrial Area Phas, E – II, New Delhi, Delhi, India – 110020
- IndustryPharma, Pharmaceutical Retailers & Distributors
To see the full contact details of Ursapharm India Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Ursapharm India is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Ursapharm India Private Limited, buy the company report.
Financials of Ursapharm India Private Limited
FY 2025 filings availableUrsapharm India Private Limited reported revenue of ₹6.22 Cr (down 23% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR)
Revenue has declined at a compounded annual rate (CAGR) of 8% over five years, including a 23% fall in the latest year. EBITDA rose 138% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹69 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹58.3 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 11.1% | ||||
| Net Profit Margin | 9.4% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Ursapharm India Private Limited, buy the company report.
Board of directors of Ursapharm India Private Limited
Ursapharm India has 3 current directors and 5 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Uwe Hurth | Director | 05 Dec 2017 | 8 Years 10 Months | Current |
| Boris Georg Roeder | Director | 27 Sep 2006 | 20 Years 0 Months | Current |
| Rohit Jain Also directs: Rajkamal Overseas LLP, Ananya Land Holdings Private Limited, Ibiza Hotels and Real Estate Developers Private Limited and 5 more | Managing Director | 01 Apr 2020 | 6 Years 6 Months | Current |
Peer comparison
Ursapharm India Private Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Sach Pharmatech Private Limited | ₹6.24 Cr (FY 2025) | 41.0% | Delhi, India | |||
| 6Ipain Healthcare Private Limited | ₹6.24 Cr (FY 2024) | -20.0% | Delhi, India | |||
| Perfocon Pharma Private Limited | ₹6.24 Cr (FY 2025) | -10.0% | Agra, Uttar Pradesh, India | |||
| Horn Bill Pet Needs Private Limited | ₹6.23 Cr (FY 2024) | -13.0% | Bangalore, Karnataka, India | |||
| Ursapharm India Private Limitedthis company | ₹6.22 Cr (FY 2024) | ₹58.3 Lakh | 9.4% | -23.0% | New Delhi, Delhi, India | |
| G D H Pharma Private Limited | ₹6.17 Cr (FY 2025) | -9.0% | Delhi, India |
To see the full peer comparison of Ursapharm India Private Limited, buy the company report.
Auditor
Ursapharm India Private Limited is audited by AHUJA SURI & TARNEJA for the financial year 2019.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| AHUJA SURI & TARNEJA | FY 2019 | 005889N |
Shareholding
The shareholding of Ursapharm India Private Limited is on record for 3 financial years, the latest being FY 2019, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2019 | FY 2017 | FY 2016 |
|---|---|---|---|
| Promoters | |||
| Domestic institutional investors (DII) | |||
| Foreign institutional investors (FII) | |||
| Public | |||
| Others |
To see the full shareholding pattern of Ursapharm India Private Limited, buy the company report.
Deals & funding
Ursapharm India Private Limited has 2 deals on record (2 funding rounds), with disclosed funding of ₹1.19 Cr; the latest was in May 2009.
Deals on record (2 of 2)
| When | Deal | Amount | Parties |
|---|---|---|---|
| May 2009 | Funding round | ₹76 Lakh | Investors: Ursapharm Arzneimittel Gmbh, 2 individuals |
| Nov 2007 | Funding round | ₹42.6 Lakh | Investors: Ursapharm Arzneimittel Gmbh, 2 individuals |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Ursapharm India Private Limited has 5 court cases on record: 4 filed by Ursapharm India, 1 filed against it. 2 cases are pending and 3 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 3 | 0 | 2 |
| District courts | 2 | 1 | 0 |
Cases on record (5 of 5)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Delhi | Writ petition | Filed by the company against National Pharmaceutical Pricing Authority & Ors. | Pending |
| High Court of Delhi | Writ petition | Filed by the company against National Pharmaceuticals Pricing Authority & Ors. | Pending |
| District court, South East, Delhi | Criminal case | Filed by the company against State | Disposed |
| District court, South East, Delhi | Civil suit | Filed against the company by an individual | Disposed |
| High Court of Delhi | Writ petition | Filed by the company against Employees State Insurance Corporation | Disposed |
To see the full case history of Ursapharm India Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Ursapharm India Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Ursapharm India has 5 GST registrations: 4 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AAACU8541M1ZX | Delhi | Active | 01 Jul 2017 |
| 21AAACU8541M1Z7 | Odisha | Active | 24 May 2018 |
| 36AAACU8541M1ZW | Telangana | Active | 25 May 2018 |
| 24AAACU8541M1Z1 | Gujarat | Active | 23 Feb 2021 |
To see the full GST registrations and return filing status of Ursapharm India Private Limited, buy the company report.
Recent activity
Ursapharm India Private Limited has 8 board changes on record since 2006: 3 appointments and 5 cessations. The latest: Rohit Jain ceased to be Additional Director on 20 Jun 2020.
Frequently asked questions
Ursapharm India is an active foreign private limited company based in New Delhi, Delhi, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 27 September 2006 (20+ years old) and is registered under CIN U24232DL2006FTC154392.
Ursapharm India has 3 current directors:
- Rohit Jain - Managing Director
- Uwe Hurth - Director
- Boris Georg Roeder - Director
The latest financial statements of Ursapharm India on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 28 November 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Ursapharm India is 07AAACU8541M1ZX, registered in Delhi. The company has 5 GST registrations in all, of which 4 are active and 1 is cancelled or inactive. Other active GSTINs include 21AAACU8541M1Z7 (Odisha), 36AAACU8541M1ZW (Telangana), 24AAACU8541M1Z1 (Gujarat).
The CIN (Corporate Identification Number) of Ursapharm India is U24232DL2006FTC154392. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Ursapharm India has 5 court cases on record: 4 filed by the company and 1 filed against it. 2 are pending. Most are in the high courts.
Ursapharm India was incorporated on 27 September 2006, making it 20+ years old. It is registered with the Registrar of Companies, Delhi.
Ursapharm India has 2 deals on record (2 funding rounds), with disclosed funding of ₹1.19 Cr; the latest was in May 2009.
The peers of Ursapharm India by revenue are Sach Pharmatech Private Limited, 6Ipain Healthcare Private Limited, Perfocon Pharma Private Limited, Horn Bill Pet Needs Private Limited, G D H Pharma Private Limited, all in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading).
Rohit Jain ceased to be Additional Director on 20 Jun 2020. Jarnail Singh ceased to be Managing Director on 19 Jun 2020. Rohit Jain was appointed as Managing Director on 01 Apr 2020. Ursapharm India has 8 board changes on record in total.
Ursapharm India can be reached through the website ursapharm.in. Its registered office is in New Delhi, Delhi, India.